Otonomy Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update

Back to Jobs

Type C meeting completed with FDA for OTIVIDEX™  in Ménière’s disease Consistent with prior guidance, pivotal trial for OTIVIDEX to start mid-2018 Conference call and webcast today at 4:30 p.m. EST SAN DIEGO , March 08, 2018 (GLOBE NEWSWIRE) — Otonomy , Inc. (NASDAQ:OTIC), a biopharmaceutical

Apply Now